Atridia

CompanyAustralia

Atridia develops 2 assets, the furthest in phase 3 (HRS-1893 in obstructive hypertrophic cardiomyopathy (oHCM)). Mostly small molecule and peptide; based in Australia.

2
Assets
Furthest stage
Phase 3
3
Trials
1
Signal

Pipeline

2
  • HRS-1893

    Inhibits cardiac myosin to reduce excessive heart muscle contraction.

    Phase 3, Small molecule, obstructive hypertrophic cardiomyopathy (oHCM), hypertrophic cardiomyopathy (Phase 2)

  • HRS-5817

    Investigational therapy for obesity

    Phase 1, Peptide, obesity, overweight

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials3
  • Signals5
  • Similar companies6

Intelligence